Respiratory Tract Diseases  >>  dilmapimod (SB-681323)  >>  Phase 2
Welcome,         Profile    Billing    Logout  

2 Trials

Remove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
dilmapimod (SB-681323) / GSK
NCT00144859 / 2004-002769-18: Safety And Anti-Inflammatory Effect Of SB681323 In Patients With Chronic Obstructive Pulmonary Disease (COPD)

Completed
2
82
Europe
SB681323
GlaxoSmithKline
Pulmonary Disease, Chronic Obstructive, Chronic Obstructive Pulmonary Disease (COPD)
 
 
NCT00996840: SB-681323 IV for Subjects at Risk of Acute Lung Injury or ARDS

Completed
2
77
US
SB-681323 Intravenous 3mg, SB-681323 Intravenous 7.5 mg, SB-681323 Intravenous 7.5mg, SB-681323 Intravenous 10mg, Placebo
GlaxoSmithKline
Lung Injury, Acute
02/13
02/13

Download Options